Annovis Bio Inc. Advances Phase 3 Alzheimer’s Trial and Reports Q2 2025 Financial Results
TL;DR
Annovis Bio's progress in Phase 3 trials for Alzheimer’s therapy and increased cash reserves position it as a strong contender in neurodegenerative disease treatment development.
Annovis Bio's Phase 3 trial for Alzheimer’s disease has enrolled 38 patients across 76 U.S. sites, with a 50% screen failure rate as anticipated.
Annovis Bio's innovative therapies for neurodegenerative diseases like Alzheimer’s aim to significantly improve patient outcomes and enhance quality of life globally.
Annovis Bio showcased four scientific posters at AAIC 2025 and expanded its team with a director of biostatistics, marking significant strides in Alzheimer’s research.
Found this article helpful?
Share it with your network and spread the knowledge!
Annovis Bio Inc. (NYSE: ANVS), a late-stage clinical drug platform company focused on neurodegenerative diseases, has provided updates on its Phase 3 trial for early Alzheimer’s disease and its financial performance for the second quarter of 2025. The company reported that its pivotal Phase 3 trial, identified by the clinical trial number NCT06709014, has secured 76 U.S. sites, with 46 actively enrolling patients. To date, 38 patients have been dosed, and nearly 200 are in the screening process, with enrollment progressing as planned and a screen failure rate of 50%, which was anticipated.
In addition to trial advancements, Annovis Bio has achieved several milestones, including the presentation of four scientific posters at the AAIC 2025 conference, the appointment of a director of biostatistics, and the hosting of a trial update webcast. The company also announced the expansion of its intellectual property portfolio with global coverage for crystal buntanetap, a key component of its therapeutic pipeline.
Financially, Annovis Bio reported a strong position with cash and equivalents totaling $17.1 million as of June 30, 2025, an increase from $10.6 million at the end of 2024. The company's research and development expenses for the quarter were $5.2 million, down from $5.8 million in the same period the previous year, while general and administrative expenses decreased to $1.1 million from $2.0 million. The net loss per share improved to $0.32 from $0.44 in the prior-year period.
These developments underscore Annovis Bio's dedication to addressing the challenges of neurodegeneration in diseases such as Alzheimer’s and Parkinson’s. The progress in the Phase 3 trial and the strengthening of the company's financial and intellectual property positions are critical steps toward the development of innovative therapies that could significantly improve patient outcomes and quality of life. For more information on Annovis Bio's initiatives and financial results, visit https://ibn.fm/iO1TH.
Curated from InvestorBrandNetwork (IBN)
